U.S. Patent Approval for its Formulation of Latanoprost in its Proprietary Controlled Release Insert

BioLight announces that ViSci, its wholly owned subsidiary, has been informed that a patent number 8,722,739 covering the proprietary formulation of Latanoprost,the medication contained in its controlled release insert for the treatment of Glaucoma, has been granted by the U.S. Patent and Trademark Office. The patent is intended to protect, inter …

Continue reading

BioLight Raises NIS 19 Million

BioLight announces the successful completion of an equity financing that raised gross proceeds of approximately NIS 19 million (USD 5.5 million).

Separately, BioLight announces that its subsidiary, IOPtima Ltd. a developer of minimally invasive ophthalmic surgery devices, received China Food and Drug Administration (CFDA) approval to market and sell the IOPtiMate™ …

Continue reading

BioLight Begins Trading on OTCQX®

BioLight has chosen to have its American Depositary Receipts (ADRs) trade on OTCQX®.

BioLight ADRs, where each ADR represents 100 ordinary shares, begin trading today under the symbol “BLGTY” on OTCQX International, a segment of the OTCQX marketplace reserved for high-quality non-U.S. companies that are listed on a qualified international …

Continue reading

DiagnosTear Starts Clinical Study

BioLight announced that DiagnosTear Ltd. has received all necessary approvals from Sheba Medical Center near Tel Aviv to begin a clinical study with its TeaRx, point-of-care Dry Eye Syndrome diagnostic assay.

The purpose of the study is to validate the effectiveness of the test methods developed by DiagnosTear in the tears …

Continue reading